RT Journal Article
SR Electronic
A1 Buckely, Rita
T1 Long-Term Injection-Free Subcutaneous Delivery of Exenatide via ITCA 650 Improves Compliance and Controls Glycemic Parameters and Weight
JF MD Conference Express
YR 2011
FD SAGE Publications
VO 11
IS 8
SP 12
OP 13
DO 10.1177/155989771108006
UL http://mdc.sagepub.com/content/11/8/12.abstract
AB Exenatide therapy in patients with type 2 diabetes who take metformin requires twice-daily self-injections and is associated with significant nausea and vomiting [Pinelli NR, Hurren KM. Ann Pharmacother 2011]. Continuous delivery of exenatide was evaluated in a Phase 2, randomized study with ITCA 650, a subcutaneous osmotic delivery system that provides constant delivery of exenatide at specified doses [ITCA 650; NCT00943917].